Unknown

Dataset Information

0

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.


ABSTRACT: Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, as part of the Myeloma Genome Project, we have defined DNA drivers of aggressive clinical behavior. Whole-genome and exome data from 1273 NDMM patients identified genetic factors that contribute significantly to progression free survival (PFS) and overall survival (OS) (cumulative R2 = 18.4% and 25.2%, respectively). Integrating DNA drivers and clinical data into a Cox model using 784 patients with ISS, age, PFS, OS, and genomic data, the model has a cumlative R2 of 34.3% for PFS and 46.5% for OS. A high-risk subgroup was defined by recursive partitioning using either a) bi-allelic TP53 inactivation or b) amplification (≥4 copies) of CKS1B (1q21) on the background of International Staging System III, comprising 6.1% of the population (median PFS = 15.4 months; OS = 20.7 months) that was validated in an independent dataset. Double-Hit patients have a dire prognosis despite modern therapies and should be considered for novel therapeutic approaches.

SUBMITTER: Walker BA 

PROVIDER: S-EPMC6326953 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Walker Brian A BA   Mavrommatis Konstantinos K   Wardell Christopher P CP   Ashby T Cody TC   Bauer Michael M   Davies Faith F   Rosenthal Adam A   Wang Hongwei H   Qu Pingping P   Hoering Antje A   Samur Mehmet M   Towfic Fadi F   Ortiz Maria M   Flynt Erin E   Yu Zhinuan Z   Yang Zhihong Z   Rozelle Dan D   Obenauer John J   Trotter Matthew M   Auclair Daniel D   Keats Jonathan J   Bolli Niccolo N   Fulciniti Mariateresa M   Szalat Raphael R   Moreau Phillipe P   Durie Brian B   Stewart A Keith AK   Goldschmidt Hartmut H   Raab Marc S MS   Einsele Hermann H   Sonneveld Pieter P   San Miguel Jesus J   Lonial Sagar S   Jackson Graham H GH   Anderson Kenneth C KC   Avet-Loiseau Herve H   Munshi Nikhil N   Thakurta Anjan A   Morgan Gareth G  

Leukemia 20180702 1


Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, as part  ...[more]

Similar Datasets

| S-EPMC6142458 | biostudies-literature
| S-EPMC11552351 | biostudies-literature
| S-EPMC9038663 | biostudies-literature
2011-08-19 | E-GEOD-8991 | biostudies-arrayexpress
2011-08-20 | GSE8991 | GEO
| S-EPMC10163277 | biostudies-literature
| S-EPMC10730063 | biostudies-literature
| S-EPMC11897644 | biostudies-literature
| S-EPMC5058940 | biostudies-literature
2023-03-01 | GSE147841 | GEO